Natalie Halladin
Overview
Explore the profile of Natalie Halladin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Billings L, Agner B, Altuntas Y, Gron R, Halladin N, Klonoff D, et al.
J Diabetes Sci Technol
. 2020 Feb;
15(3):636-645.
PMID: 32107930
Background: Insulin degludec/liraglutide (IDegLira) results in glycated hemoglobin (HbA1c) levels comparable with basal-bolus (BB) therapy. Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 ...
2.
Sesti G, Bardtrum L, Dagdelen S, Halladin N, Haluzik M, orsy P, et al.
Diabetes Obes Metab
. 2020 Jan;
22(5):873-878.
PMID: 31903724
This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII...
3.
Aroda V, Gonzalez-Galvez G, Gron R, Halladin N, Haluzik M, Jermendy G, et al.
Lancet Diabetes Endocrinol
. 2019 Jun;
7(8):596-605.
PMID: 31189519
Background: Durability of glycaemic control might reduce disease burden and improve long-term outcomes. DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar...
4.
Philis-Tsimikas A, Billings L, Busch R, Morales Portillo C, Sahay R, Halladin N, et al.
Diabetes Obes Metab
. 2019 Feb;
21(6):1399-1408.
PMID: 30761720
Aim: To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy. Materials And Methods: In...
5.
Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, et al.
Endocr Pract
. 2018 Nov;
25(2):144-155.
PMID: 30383495
Objective: The efficacy and safety of insulin degludec/liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients...
6.
Billings L, Doshi A, Gouet D, Oviedo A, Rodbard H, Tentolouris N, et al.
Diabetes Care
. 2018 Feb;
41(5):1009-1016.
PMID: 29483185
Objective: In patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus...
7.
Ekeloef S, Halladin N, Fonnes S, Jensen S, Zaremba T, Rosenberg J, et al.
J Cardiovasc Transl Res
. 2017 Oct;
10(5-6):470-479.
PMID: 29027116
Melatonin has attenuated myocardial ischemia reperfusion injury in experimental studies. We hypothesized that the administration of melatonin during acute myocardial reperfusion improves myocardial salvage index in patients with ST-elevation myocardial...
8.
Harris S, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, et al.
Diabetes Obes Metab
. 2017 Jan;
19(6):858-865.
PMID: 28124817
Aims: To compare the safety and efficacy of a simpler titration algorithm for insulin degludec/liraglutide (IDegLira) with that used in previous DUAL trials in insulin-naïve patients with type 2 diabetes....